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Introduction: Cartilage protein distribution and the changes that occur in cartilage ageing and disease are
essential in understanding the process of cartilage ageing and age related diseases such as osteoarthritis. The aim
of this study was to investigate the peptide profiles in ageing and osteoarthritic (OA) cartilage sections using matrix
assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI).
Methods: The distribution of proteins in young, old and OA equine cartilage was compared following tryptic
digestion of cartilage slices and MALDI-MSI undertaken with a MALDI SYNAPT™ HDMS system. Protein identification
was undertaken using database searches following multivariate analysis. Peptide intensity differences between
young, ageing and OA cartilage were imaged with Biomap software. Analysis of aggrecanase specific cleavage
patterns of a crude cartilage proteoglycan extract were used to validate some of the differences in peptide intensity
identified. Immunohistochemistry studies validated the differences in protein abundance.
Results: Young, old and OA equine cartilage was discriminated based on their peptide signature using discriminant
analysis. Proteins including aggrecan core protein, fibromodulin, and cartilage oligomeric matrix protein were
identified and localised. Fibronectin peptides displayed a stronger intensity in OA cartilage. Age-specific protein
markers for collectin-43 and cartilage oligomeric matrix protein were identified. In addition potential fibromodulin
and biglycan peptides targeted for degradation in OA were detected.
Conclusions: MALDI-MSI provided a novel platform to study cartilage ageing and disease enabling age and disease
specific peptides in cartilage to be elucidated and spatially resolved.Introduction
Osteoarthritis (OA) is an age related joint disease cha-
racterized by alterations in the chondrocytes and loss of
cartilage extracellular matrix (ECM) [1]. Age is the most
common risk factor for its initiation and progression,
with symptomatic OA affecting 10 to 20% of people
more than 50 years old [2]. ‘Wear and tear’ injuries due
to mechanical loading over many years, genetic poly-
morphisms and other factors contribute to the develop-
ment of the disease.
Although much work has been undertaken to inves-
tigate the pathogenesis of OA the molecular me-
chanisms involved are not fully understood, with few* Correspondence: peffs@liv.ac.uk
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reproduction in any medium, provided the orvalidated markers for disease diagnosis and progression
being available. Treatment of OA is limited to pain relief
with few disease-modifying therapeutics available to pa-
tients. Hence, methodologies which permit the detailed
study of aging and OA cartilage organization could im-
prove the knowledge of how aging increases the risk of
OA. Previously the comparison of young, old and OA tis-
sue has been challenging as the provision of normal old
and old OA is difficult and few markers have been iden-
tified that differentiate between age or disease-related
change in cartilage except urinary collagen type II [3].
Measurement tools enabling the capture of the dy-
namic and complex interplay between proteins, lipids,
DNA and other molecules are necessary. This interplay
involves the appearance, interaction and disappearance
of many species on varying time scales. Capturing this
spatial and temporal information will help in the questLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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provide disease modifying treatments. Mass spectro-
metry (MS) is an analytical tool that enables the accurate
measurement of the mass-to-charge ratio of ions. Matrix
assisted laser desorption/ionization mass spectrometry
imaging (MALDI-MSI) of tissue samples is a powerful
technique that allows for spatially resolved, compre-
hensive and specific characterization of hundreds of
unknown molecular species (proteins, peptides, lipids or
metabolites) in situ in a single molecular imaging experi-
ment [4]. The label-free nature of the technique com-
bined with high spatial resolving power better than 50
micrometer makes it an ideal tool to study the molecular
aspects of aging in cartilage tissue [5]. Specific protein
patterns revealed by MSI have been demonstrated as
prognostic [6] and diagnostic indicators [7]. MSI tech-
niques have only recently been implemented in cartilage
research. One study employed a time of flight secondary
ion mass spectrometry (TOF-SIMS) workflow in order
to acquire molecular-specific spatial distribution of lipids
in normal and OA cartilage [8]. A further study used
MALDI-MSI to identify and study OA specific peptides
and proteins in cartilage [9]. In this and other works, a
direct correlation between the detected peptides and the
distribution and identity of the original precursor pro-
tein was achieved [10].
The horse provides an excellent model for the study of
cartilage in man as it suffers clinical joint diseases simi-
lar to man [11] and, as such, has been used as a model
of naturally occurring OA [12] due to the extensive
knowledge of its pathogenesis and clinical experience of
the disease [13]. Indeed, the incidence of equine meta-
carpophalangeal OA in young racehorses [14] in training
is similar to the incidence of post traumatic OA in man
[15]. Additionally, the articular cartilage thickness is also
comparable between the species [16].
The aim of this study was to establish peptide profiles
in young, aging and OA horse cartilage of full thickness
cartilage from surface to bone, with a high spatial distri-
bution to determine changing molecular events distinct
between aging and disease. We hypothesize that many
alterations in specific peptide abundance are due to pro-
teinase driven degradation.
Methods
Sample collection, preparation and processing
Ethical approval was not required for this study as
samples were obtained from an abattoir. Full thickness
equine cartilage slices were removed from the mid con-
dyle region of metacarpophalangeal joints collected from
an abattoir and snap frozen in liquid nitrogen within
hours. All samples were scored macroscopically using
Kawcak scoring for pathological grading of the distal
condyles of metacarpophalageal III [17]. For age-relatedstudies, samples were taken from skeletally mature
young (four years old, n = 3) and old (greater than fifteen
years old, n = 3) horses. For OA studies, old normal
samples were taken from macroscopically and micro-
scopically normal condylar areas adjacent to diseased tis-
sue (n = 3) (greater than 15 years old). For young horses,
one year is equivalent to an age of approximately
3.5 years of a human [18]. Hence, horses more than
15 years old used in this study equate to humans of
older than 52 years. For OA studies, skeletally mature
donors >15 years were chosen with mild macroscopic
OA changes.
Cartilage was sectioned perpendicular to the joint sur-
face at 12 μm thicknesses on a cryostat Microm HM 525
(Microm International, Walldorf, Germany) and thaw
mounted on glass slides. All samples were dried in a
vacuum desiccator for 10 minutes prior to further
processing.
Tissue digestion, matrix deposition and MALDI-MSI
Young and old cartilage was studied in duplicate while old
and OA cartilage was examined in triplicate and then
compared by MALDI-MSI. The sections were washed in
70% ethanol and chloroform for 30 seconds each. Tissue
digestion and matrix deposition and MALDI-MSI were
undertaken as previously described [9].
Multivariate analysis and data interpretation following
MALDI-MSI
Data pre-treatment, principal component analysis (PCA)
and discriminant analysis (DA) were performed using
AMOLF in-house build MATLAB (The MathWorks,
Natick, MA, USA) software tools [9]. The first 20 prin-
cipal components (PC) were used as input for discri-
minant analysis (DA). PCA was performed on the raw
spectral data and was used as a data compression and
noise filtering step before application of DA. In short,
PCA is an unsupervised statistical method that aims at
pooling together a maximum amount of variance in a
minimum number of independent variables. These new
variables (principal components) are a construct of the
original variables (mass channels) weighed by their cor-
respondence with the new variable. This weighing factor
is referred to as the PC loading. DA is a supervised
multivariate method that calculates the combination of
variables (in this case PCs) which gives maximum sepa-
ration between the pre-defined groups. DA maximizes
the between group - within group variance.
Biomap 3.7.5.5 software (Novartis Pharma AG, Basel,
Switzerland) was used to generate ion images. Norma-
lization of the intensity of all m/z channels was performed
using the intensity of the m/z 190 matrix peak. P values
for statistical differences found in MALDI-MSI experi-
ments were calculated with one-way analysis of variance
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(SPSS Inc. Chicago IL, USA) following normality testing.
Differences were considered to be statistically significant
at P ≤0.05. The data were expressed as mean intensity ±
standard error.
Tissue digestion and matrix deposition for profiling
experiments
Protein identification was undertaken with profiling ex-
periments directly from each donor tissue by applying
10 μL of trypsin diluted in 25 mM ammonium bicarbon-
ate 0.05 μg/μL directly and incubating overnight at 37°C.
α-Cyano-4-hydroxycinnamic acid (CHCA) matrix was ap-
plied as previously described [9]. Data dependent analysis
(DDA) of tryptic peptides was performed with the MALDI
SYNAPT™ HDMS system. Every MS survey scan was fol-
lowed by collisional fragmentation of the most intense
ions with subsequent collection of tandem mass spec-
troscopy (MS/MS) spectra. Direct MS/MS fragmentations
were performed directly from the tissue on the peptides
that differentiate young, old or OA tissue. These target
peptides were found following DA. In addition, fragmenta-
tion was also undertaken on a peptide list generated from
bibliographical analysis of previous MALDI-MSI studies
in cartilage [9]. The resulting data files were submitted to
an in-house Mascot server (Matrix Sciences, London, UK)
and searched against the Unihorse and Swissprot data-
bases. Search parameters used were: peptide mass toleran-
ces 50 ppm, fragment mass tolerance of 0.5 Da, 1+ ions,
missed cleavages; 3, and instrument type MALDI-Q-TOF.
Modifications used were variable oxidation of methionine.
Histological staining and immunohistochemistry studies
Following MSI the tissue sections were washed in 70%
ethanol for five minutes to remove matrix. The slides
were immersed in Harris hematoxylin solution (Sigma-
Aldrich, Dorset, UK) for one minute. After washing with
water for 15 minutes, they were rinsed in 95% ethanol
and counterstained in an eosin solution for 30 seconds.
Digital images were acquired with the Mirax system
(Carl Zeiss, Sliedrecht, The Netherlands) after dehydra-
ting steps. A score based on the modified Mankin’s sco-
ring system for semi-quantitative histological assessment
of all equine cartilage samples was undertaken [19].
Macroscopic grading was used to allocate samples into
normal or OA groups, and scores of greater than 0 were
assigned OA. Only macroscopically normal cartilage was
used for age related studies. All samples for age related
studies had a modified Mankin’s grade of 0 (data not
shown). The macroscopic grading and Mankin’s score
for each sample used in the old normal versus OA stu-
dies are shown in Additional file 1: Table S1.
To perform immunohistochemistry studies, paraffin-
embedded tissues were cut into 4 μm sections by amicrotome. Protease antigen retrieval was undertaken
with a bacterial protease solution. Sections were incubated
with polyclonal rabbit anti-human fibronectin (Dako,
Heverlee, Belgium) at 1:2400 dilution, overnight at 4°C.
Goat anti-rabbit biotinylated secondary antibody at 1:100
was incubated at room temperature for 30 minutes. Im-
munostaining was detected with avidine-biotin complex
(Vector Laboratories, Peterborough, UK) and chromo-
genic substrate diaminobenzidine (Sigma-Aldrich, Dorest,
UK). Counterstaining was undertaken with Papanicolau
stain (Merck Millipore, Watford, UK). Negative control
experiments were carried out with omission of the pri-
mary antibody and substitution with non-immune rabbit
immunoglobulin G (IgG) (Abcam, Cambridge, UK). No
staining was observed in negative control experiments.
Digital images were visualized and acquired with a Nikon
DS-L2 stand-alone control unit using a Nikon eclipse 80i
microscope. Analysis was undertaken with ImageJ. ImageJ
1.42 image software and band densitometry was analyzed
by arbitrarily drawing a rectangular box around the se-
lected protein bands of interest. The same rectangular box
was used to measure all bands of interest and band in-
tensities were quantified by conversion to profile plot
histograms. By specifically selecting the peak of interest
and closing off the peak with the line tool, background-
subtracted density of each peak of interest is quantified.
All densitometry data are normalized to the band intensity
of the loading control used.
Proteoglycan-enriched fraction isolation from cartilage
In order to validate our hypothesis that the reduction in
specific peptides identified by MALDI-MSI was due to
degradation of those specific peptides we undertook
proteinase digestion of proteoglycan-enriched cartilage.
Equine articular cartilage from the grossly normal metacar-
pophalangeal joint of three horses, mean age 10 ± 1 years,
obtained from an abattoir was pooled and pulverized with
a dismembranator (Miko, S-Braun, Bethlehem, PA, USA).
Proteins were extracted with cartilage extraction buffer
containing 4 M guanidinium chloride, 50 mM sodium
acetate and proteinase inhibitors (complete protease inhib-
itors, ethylenediaminetetraacetic acid (EDTA)-free, Roche,
Lewes, UK), pH 6.0 using end-over-end mixing for 20 hours
at 4°C. After extraction the soluble fraction (proteoglycan-
enriched) was removed following centrifugation for 15 mi-
nutes at 13,000 g at 4°C. Following dialysis in a 14,000-kD
cut-off membrane (Spectrapor, Breda, NL) for 24 hours at
4°C against 0.1 M sodium acetate, pH 6.0 in the presence
of proteinase inhibitors, the extract was clarified using
centrifugation for 15 minutes at 13,000 g at 4°C. A crude
proteoglycan-enriched extract was isolated by associative
cesium chloride (CsCl) density gradient centrifugation [20],
also in the presence of the proteinase inhibitors. The
supernatant was fractionated in an associative CsCl density
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100,000 g in an ultracentrifuge (Beckman 50Ti, Galway,
Ireland). The tube was fractionated into quarters, A1-A4
[21], and the A1-A2 fraction dialyzed first against 0.1 M
sodium acetate for 48 hours at 4°C and then against ultra-
pure water for 36 hours at 4°C, both in the presence of
proteinase inhibitors. The samples were then lyophilized.
Proteinase digestion of the proteoglycan-enriched
fraction in vitro
A reconstituted A1-A2 aliquot was digested in proteinase
digestion buffer (50 mM Tris HCl, 100 mM NaCl, 10 mM
CaCl2, pH 7.5) with 0.014 nmol truncated human recom-
binant ADAMTS-4 (a distintegrin and metalloproteinase
with thrombospondin motifs 4) (Calbiochem, La Jolla,
CA, USA) for seven hours at 37°C. A control aliquot was
incubated under the same conditions in the presence of
recombinant protein formulation buffer. The enzymatic
digestion reactions (1 ml) were stopped by addition of
EDTA.
In-solution tryptic digestion
The crude proteoglycan extracts following from the pro-
teinase digestion were easily trypsin digested as previously
described [22]. Samples were desalted and purified using
C18 resin in the form of a ZipTip® (Merck Millipore,
Rockland, MA, USA).
LC-MS/MS analysis of proteinase digested cartilage
proteoglycan-enriched fraction
Liquid chromatography (LC)-MS/MS analysis was per-
formed using NanoAcquity™ Ultraperformance LC
(Waters, Manchester, UK) on line to an LTQ-Orbitrap
Velos (Thermo-Fisher Scientific, Hemel Hempstead,
UK) as described previously [22].
Data analysis proteinase digested cartilage
proteoglycan-enriched fraction
In order to identify potential cleavage sites of ADAMTS-4
identification raw spectra were converted to mascot gene-
rated files (mgf) using Proteome Discoverer software
(Thermo, Hemel Hempstead, UK). The resulting mgf files
were searched against the Unihorse database using an in-
house Mascot [23] server (Matrix Science, London, UK).
Search parameters used were: enzyme; none, peptide mass
tolerances 10 ppm, fragment mass tolerance of 0.6 Da, 1+,
2+ and 3+ ions, missed cleavages; 1, and instrument type
ESI-TRAP. Modifications included were: fixed; carbami-
domethyl cysteine and variable; oxidation of methionine.
Patterns of fragmentation were determined for bigly-
can and fibromodulin. The probability that a match was
correct (P <0.05) was determined using the Mascot
derived ion score where P was the probability that the
observed match was a random event.To validate the results further, raw data files were loaded
into PEAKS® Studio 6.0 (Bioinformatics Solutions Inc.,
Waterloo, Canada) and de novo sequencing and protein
identification performed. PEAKS® software employs mul-
tiple analytical algorithms and is able to identify every
peptide in the data, and can validate database searches
using de novo sequencing results. Estimate false discovery
rate (FDR) function was used in order to create a ‘decoy
fusion’ database based on the Unihorse database. Data
prerefinement was undertaken by choosing peak centroi-
ding, charge deconvolution, and deisotope options. The
quality value was set greater than 0.65. The search para-
meters for the PEAKS® software were identical to those
for the Mascot search. Results generated using PEAKS®
Studio were manually curated against the MASCOT
search engine results. Only peptides with a 10lgP score
of >20 were considered as significant [24].Results
Peptide identification
MS/MS profiling experiments on cartilage slices were
undertaken in order to determine proteins that could be
identified directly from the tissue (Table 1). Tryptic pep-
tides of cartilage oligomeric matrix protein (COMP)
and fibromodulin were identified in all groups. Follo-
wing PCA and DA between young, old and OA groups,
young and old, and old and OA, the peaks with the
highest absolute loadings in the DF1 spectra were tar-
geted directly from tissue slices for MS fragmentation
and database searching in order to identify the protein
it pertained to. In addition, a list of masses was also se-
lected that had been previously identified in human car-
tilage MALDI-MSI studies (Table 1) [9].MALDI-MSI reveals the peptide signature in young, old
and OA cartilage
Young, old and OA cartilage
After imaging experiments, data from young, old and OA
cartilage groups were analyzed together. The spectra of
each group revealed different profiles. A combined spec-
trum of representative digested equine young, old and OA
samples is demonstrated in Additional file 2: Figure S1.
PCA analysis and a scatter plot of DF1-DF2 revealed
differences between each sample type (Additional file 3:
Figure S2A and B). In addition, a comparison between
biological repeats of the same subgroup was undertaken
to assess the reproducibility of the score distribution of
independent samples (data not shown).
Following DA a number of peaks were detected as
specific for young, old or OA groups (Figure 1A). A pep-
tide specific to young samples with m/z 2414.9 was sub-
sequently identified as collectin-43 using fragmentation
targeting of this mass (Figure 1B).









O18832_HORSE Aggrecan 2,325.3 43 R.VSLPNYPAIPTDATLELQNLR.S ✓
PGS1_HORSE Biglycan 1,312.8 41 43 K.IQAIELEDLLR.Y ✓
PGS1_HORSE Biglycan 2,027.2 47 K.NHLVEIPPNLPSSLVELR.V ✓
CILP2_HORSE Cartilage intermediate
layer protein






2,256.1 86 R.FYEGPELVADSNVVLDTTMR.Ga ✓
CHAD_BOVIN Chondroadherin 2,198.3 17 R.AGAFDDLTELTYLYLDHNK.V ✓
CO2A1_MOUSE Collagen alpha-1(II)
chain




CL-43_BOVINE Collectin 43 2,415.0 33 K.GEPGPEGGVGAPGMPGSPGPAGLKGER.G ✓
FMOD_BOVIN Fibromodulin 1,557.0 67 42 R.SLILLDLSYNHLR.K ✓
FMOD_BOVIN Fibromodulin 1,955.2 67 74 K.IPPVNTNLENLYLQGNR.Ia ✓








The proteins identified following profiling and targeted MS studies from cartilage are represented. The table identifies the Swissprot accession number,
abbreviation of the protein name, experimental molecular weight of the matched peptides, the score given by the Mascot algorithm and the sequence of the
matched peptides. All Mascot scores were significant (P <0.05). All peptide sequences were checked against the equine sequence and were homologous.
adenotes peptides previously identified in a human cartilage MALDI-IMS study [9]. MS, mass spectrometry; MS/MS, tandem mass spectroscopy.
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and DA between young and old, and old and OA groups
separately.Young and old cartilage
Differential peptide distributions between young and
old cartilage were assessed by MALDI-MSI followed by
DA. The resulting DF1 classified the data into young
and old (Figure 1C). The DF1 spectra (Figure 1D) iden-
tified that the peaks of the positive part of the DF1 were
specific from young cartilage samples, such as collectin-
43, and the peaks of the negative part were more abun-
dant in cartilage from old donors.
The peak distribution intensity differences in young,
old and OA cartilage of the identified peptides in Table 1
were analyzed by Biomap software. While there was no
difference in the intensity of the majority of the peptides
between groups, including collagen type II, a signifi-
cantly different intensity of peptides for COMP, m/z
2256.1 and biglycan 2027.2 was observed (Figure 2).Old and OA cartilage
The data were assigned to two groups (OA and old) and
DA was performed (Figure 3). The positive part of DF1
showed the masses specific to OA, the negative part the
masses specific to the old group.
Of these, peptide m/z 1366.5 was found to be imaged
with Biomap at greater intensities in all OA samples
(mean intensity 1.01 ± 0.03), P <0.001, young or old ver-
sus OA). Mean intensity for young was 0.05 ± 0.003 and
old 0.06 ± 0.04 (Additional file 4: Figure S3). In addition,
we checked other peptides as found in other studies on
human samples [9]. Distinctive intensity differences were
observed for the previously identified fibromodulin pep-
tide ELHLDHNQISR, m/z 1361.7. This peptide is ho-
mologous to the horse and was significantly reduced in
OA equine cartilage (Figure 4A and B). Other peptides,
such as m/z 1349.7, identified previously as a fibronectin
peptide and homologous to the horse sequence were vi-
sualized. The highest intensity differences were between
young (mean intensity 0.11 ± 0.009 and OA (mean inten-
sity 0.36 ± 0.12) samples (P = 0.018, young versus OA).
Figure 1 PCA and DA of young, old and OA cartilage. A) The spectra of all the old and OA samples after MALDI-MSI experiments were analyzed
by PCA and DA to classify peptides specific of each category using a 1 D plot. B) Loading plot of DF1 representing the peptides specific to OA given
by MALDI-MSI. The young specific peak 2415.9 is ringed. Figure C and D. PCA and DA separated the dataset on age of the sample. C) The spectra of
all the young and old samples after MALDI-MSI experiments were analyzed by PCA and DA to classify peptides specific to each age using a 1 D plot.
D) Loading plot of DF1 representing the peptides specific to age of cartilage given by MALDI-MSI. The young specific peak m/z 2414.9 is ringed. DA,
discriminant analysis; MALDI, matrix assisted desorption ionization; MSI, mass spectrometry imaging; OA, osteoarthritis; PCA, principal component
analysis.
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was also significantly different (Figure 4C and D). Interes-
tingly, a peptide m/z 1401.7 identified as fibronectin and
previously nominated as a human OA marker [9] was vi-
sualized in young, old and OA samples (Figure 4E and F).
The highest intensity differences for this peptide were bet-
ween young (mean intensity 0.09 ± 0.009) and OA (mean
intensity 0.17 ± 0.11) samples (P = 0.02, young versus OA).
The higher intensity of fibronectin peaks in OA cartilage
identified by MSI was orthogonally validated using fibro-
nectin immunohistochemical staining (Figure 5). There
was an increase in fibronectin staining in OA cartilage
compared to old cartilage (mean pixel intensity 29.5 ± 1.9
old versus 41.5 ± 1.9 OA, n = 3, P <0.05). Primary and se-
condary antibody controls indicated that the primary anti-
body was specific to the antigen and the label was specific
to the primary antibody (data not shown).Finally, we measured the intensity of the distribution
of peptides in different areas of the cartilage in young,
old and OA cartilage in order to assess if the distribu-
tions were homogenous. However, we did not find differ-
ences in peptide distribution.
Validation of fibromodulin and biglycan fragmentation
patterns
In order to validate our MALDI-MSI data and test our
hypothesis that alterations in specific peptide abundance
identified by Biomap were due to proteinase driven deg-
radation, we identified ADAMTS-4 derived fragmen-
tation patterns in fibromodulin and biglycan. A number
of ADAMTS-4 derived neopeptides were identified for
fibromodulin and biglycan which may account for the
reduction in peptide intensity identified by Biomap
(Table 2).
Figure 2 Significant differential imaging of some ECM peptides. Biomap was used to localize and quantify the differences in the peptide
peak intensity of m/z 1679.8, m/z 2256.1 and m/z 2027.2 between young, old and OA cartilages. Samples representative of each group are
illustrated here. Scale bar shows normalized intensities to 190m/z matrix peak. In the scale bar red represents the highest signal. Histograms
show the means of the relative peak intensities and 95% CI, n = 3 for each peptide. There was no change in the distribution of the type II
collagen peak m/z 1679.8. However, a significant difference was evident for the COMP peptide m/z 2256.1 (P = 0.03 young versus old and old
versus OA) and the biglycan peptide m/z 2027.2 (P = 0.02, young versus OA and old versus OA). COMP, cartilage oligomeric matrix protein; ECM,
extracellular matrix; OA, osteoarthritis; 95% CI, 95% confidence interval.
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MALDI-MSI technology has been previously used in
biomarker discovery [25] and to localize proteins, pep-
tides and lipids in normal and OA human cartilage [8,9].
A recent study used MALDI-MSI to investigate synovial
tissue from OA and rheumatoid arthritis patients resul-
ting in the identification of differentially expressed pro-
teins between the two diseases [26]. While these studies
were undertaken on cartilage from normal and late OA
adult human knees, nothing has been described until
now in relation to age-related changes in cartilage andFigure 3 PCA and DA of normal and OA cartilage. A) The spectra of all
by PCA and DA to classify peptides specific to each category using a 1 D p
given by MALDI-MSI. The OA specific peak 1366.5 is ringed. DA, discriminan
osteoarthritis; PCA, principal component analysis.MALDI-MSI. In addition, this is the first time potential
biomarkers of age and OA have been identified in car-
tilage using this technology.
Following MALDI-MSI and DA the peptide profile
of young, old and OA horse cartilages could be distin-
guished. There was also a marked difference between
the peptides identified in old versus OA as well as young
versus old groups. Interestingly, when DA was applied
to all three groups together (young, old, OA) there was a
contribution of the old samples to young and OA indi-
cating that peptides within old samples were also presentthe old and OA samples after MALDI-MSI experiments were analyzed
lot. B) Loading plot of DF1 representing the peptides specific to OA
t analysis; MSI, MALDI, matrix assisted desorption ionization; OA,
Figure 4 Relative mean peak intensity of m/z 1361.7, m/z 1349.7 and m/z 1401.7. Biomap was used to quantify the differences in the
peptide peak intensity of A) m/z 1361.7, C) m/z 1349.7 and E) m/z 1401.7 between young, old and OA cartilages. For m/z 1361.7 two donors
representative of each group are illustrated here. Scale bar shows normalized intensities to 190m/z matrix peak. Histogram of B) m/z 1361.7, D)
m/z 1349.7 and F) m/z 1401.7 shows the means of relative peak intensities and 95% CI, n = 3, *represents P <0.05 and ***represents P <0.001. OA,
osteoarthritis; 95% CI, 95% confidence interval.
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majority of the proteins in young, old and OA cartilage
will be the same ECM proteins [27]. Furthermore, pre-
vious studies have shown that tissue classified as OA still
contains areas or cells with a healthy signature [8,9].
When a peak profile comparison was made between old
and OA a distinction between OA related peptides was
made which suggests that some age-related changes in
peptides occur which do not contribute to disease re-
lated changes.
The major findings in this study were the identification
of potential degradation sites in OA cartilage in biglycan
and fibromodulin together with a number of potential
markers of both age-related and disease-associated changes
in cartilage. In addition, potential degradation sites within
specific COMP peptides were identified. COMP is a major
protein with a role in cartilage structural integrity through
its collagen I, II, IX and chondrocyte binding capacity,
interaction with other ECM proteins including matrilin-3
[28] and role in fibrillogenesis [29]. It has been proposed
as a biomarker for arthritis [30]. Interestingly, the peptides
identified were from the collagen binding C-terminal of
COMP which others have demonstrated is important inintra- and extracellular processes [31]. Indeed, mutations
in the genes encoding COMP and matrilin-3 result in
multiple epiphyseal dysplasias [31,32]. Measurement of
intact COMP and fragments thereof in synovial fluid or
serum correlates to cartilage destruction in rheumatoid
arthritis (RA) and OA patient studies [33]. Interestingly,
studies in rats have found that the plasma levels of COMP
are age dependent [34]. We observed a decrease in both
young and OA compared to old cartilage in the distribu-
tion of the COMP peptide FYEGELVADSNVVLDTTMR.
This peptide is located in the C-terminal end of COMP
which binds collagen I, IX and II, and regulates fibril
formation [29]. Our previous studies following cytokine
stimulation of mature equine cartilage explants identified
a neopeptide which indicated degradation of this peptide
at Asn712–713Thr (data not shown). This suggests that in
OA there is degradation within this tryptic peptide re-
sulting in its reduced expression, demonstrated when OA
cartilage was imaged. In young cartilage it may represent
reduced synthesis or cartilage remodelling. The peptide
represents a possible marker of age, but not disease,
related changes in cartilage ECM. Future studies will in-
vestigate this finding further with the use of specifically
Figure 5 Fibronectin validation in normal and OA cartilage.
A) A representative experiment of fibronectin immunohistochemistry
in normal and OA samples is shown. B) Quantitation of differences in
fibronectin staining between normal and OA cartilages (mean pixel
intensity and 95% CI, n = 3; *P <0.05). OA, osteoarthritis; 95% CI, 95%
confidence interval.
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MS intensities do not always reflect analyte concentration.
It is possible that alterations in the nature of the tissue in
aging and disease could influence ionization efficiency
and, hence, cause ion suppression effects [35]. However,
as our previous studies identified a degradation product
within this peptide, this is less likely.
In addition, a marker of young cartilage, peak 2414.9
identified as collectin-43, was demonstrated. Collectin-43
is a C-type serum lectin with collagenous regions and a
member of the collectin family of soluble proteins that areTable 2 A number of ADAMTS-4 derived of biglycan and fibro
and PEAKS®











adenotes a neopeptide indicating a probable cleavage site within a tryptic peptide
cleavage site is between these amino acids. ADAMTS, A distintegrin and metallopro
tandem mass spectrometry.effector molecules in innate immunity [36]. Biglycan and
decorin have been identified as binding collectin-43 and
may have an important role in the resolution of C1q-
mediated inflammatory processes in cartilage. Biglycan
and decorin may down-regulate proinflammatory effects
mediated by the collectins [37].
The study also demonstrated a reduction in some pep-
tides for biglycan and fibromodulin, in both young and
old compared to OA cartilage. Biglycan and fibromodulin
are members of the small leucine rich repeat proteoglycan
family with important collagen binding properties [38,39].
Structural changes related to aging are evident in biglycan,
where there appears to be a cleavage in the amino ter-
minal domain resulting in a ‘no-glycan’ biglycan as the
terminal peptide containing the glycosaminoglycan chain
separates from the protein core [40]. In order to study
these findings further a cartilage-derived proteoglycan-
enriched fraction was treated with the recombinant aggre-
canase ADAMTS-4 and subjected to trypsin digestion
and LC-MS/MS. In OA, the degradation of cartilage is
characterized by a loss of ECM caused by secreted prote-
ases, principally matrix metalloproteases and aggrecanases
(reviewed [41]). We hypothesized that a reduction in the
intensity of the fibromodulin tryptic peptide ELHLDHN-
QISR m/z 1361.7 and the biglycan mid-region tryptic pep-
tide NHLVEIPPNLPSSLVELR m/z 2027.2 in OA samples
was due to proteinase driven fragmentation within the
peptide. The reduction in intensity of these peptides either
represents a reduction in the synthesis, degradation from
disease or differences in ionization. However, as another
peptide identified in biglycan IQAIELEDLLR m/z 1312.7
(also mid-region) does not reveal reduced intensity in OA
it is more likely that it is lost following degradation. Thus
in OA, it is likely that there is cleavage within these tryptic
peptides resulting in a loss of this mass and so a reduction
in peak intensity.modulin were identified with LC-MS/MS using MASCOT











identified in the MALDI-MSI experiment. Amino acids in bold indicate that the
teinase with thrombospondin motifs; LC, liquid chromatography; MS/MS,
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bution imaged. The peptides m/z 1955.2 and 1361.7 cor-
respond to the fibromodulin tryptic peptides identified in
our human OA MALDI-MSI study [9]. Discrepancies in
the abundance of the peptides may be due to the stage of
OA in the two different studies. In the human study, the
OA samples represented late stage OA while here we used
lower grade early OA samples. One of a number of pep-
tides, identified in MALDI-MSI studies of human cartilage
[9], and with the same mass in the horse investigated was
the fibromodulin peptide ELHLDHNQISR m/z 1361.7.
This was significantly reduced in OA samples despite
the distribution of other fibromodulin peptides identified
being unchanged, for example with m/z 1557.0 or 1955.2
identified in profiling experiments between categories by
either DA or following peak intensity analysis and statis-
tical testing (data not shown). This, together with the
identification of an ADAMTS-4 driven cleavage site bet-
ween Asn186–187Gln would again indicate degradation of
this peptide as opposed to a reduction in synthesis of
fibromodulin. ADAMTS-4 is a pertinent enzyme in the
pathogenesis of OA and although fibromodulin has been
previously identified as a substrate for ADAMTS-4 [42],
this was at the Tyr 44–45Ala bond [43]. Degraded frag-
ments of the core fibromodulin protein have been ob-
served in OA cartilage [44] and with age [45]. Removal of
this portion of fibromodulin would result in weaker inter-
actions of collagen fibers with surrounding structures.
This illustrates the potential usefulness of MALDI-MSI in
identifying and spatially resolving novel cleavage sites with
pathological relevance. Indeed, using two different meth-
odological approaches, this study indicates that cleavage
of the fibromodulin peptide ELHLDHNQISR and the
biglycan peptide NHLVEIPPNLPSSLVELR is disease, and
not age, related. Insights such as this may aid in the
understanding of the age-related, but not age-distinct,
disease OA.
A number of tentative OA markers were detected. The
intensity of the differences in abundance of peptides with
m/z 1366.5 and 1349.7 in young, old and OA samples
found their abundance increased in OA as detected by
MALDI-MSI imaging. The m/z 1349.7 had been identified
from human studies [9] as being derived from fibronectin
and its sequence homolog confirmed between the horse
and man. Furthermore, we identified the fibronectin pep-
tide m/z 1401.7 as being more abundant in OA cartilage
compared to young but not old cartilage. In a human OA
MALDI-MSI study this peptide was elevated in OA [9].
Here, the fibronectin peptide m/z 1401.7 appears to be
affected by age-related changes. Fibronectin, an ECM
glycoprotein, and fibronectin fragments have been asso-
ciated with enhanced levels of catabolic cytokines and
up regulation of MMPs involved in both normal homeo-
stasis and arthritic diseases. Fibronectin fragments andfibronectin-aggrecan complexes have previously been sug-
gested as biomarkers of OA [46,47]. Therefore, these pep-
tides may provide promising biomarkers of OA as they
are not affected by age-related changes. Fibronectin may
provide a key species for potential diagnostic and drug tar-
gets. The increase in some fibronectin peptides identified
in OA cartilage is most likely to be due to an increase in
synthesis, according to other authors [9].
The protein melanoma inhibitory activity protein 3
(MIA3) was also identified for the first time in MALDI-
MSI studies of cartilage. This is a secreted protein ex-
pressed by chondrocytes with a fundamental role in
maintaining the chondrocyte phenotype [48]. A similar
distribution of a peptide with the same mass as MIA3,
m/z 1186.74 in young, old and OA tissue was evident
(data not shown) which was not surprising as even mature
chondrocytes secrete MIA3 [49].
This study undertook analysis on equine cartilage from
the metacarpophalangeal joint which is a high motion
joint similar to the knee in man. However, cartilage from
different joints and different species may represent a dif-
ferent set of matrix changes; hence, it was not surprising
that there were some key differences between this study
and a previous MALDI-MSI study in end stage OA hu-
man cartilage [50]. Although previous studies enabled
differential peptide resolution between superficial and
deep layers of cartilage to be identified, this was not pos-
sible using equine cartilage from the metacarpal joint.
This was due to the thickness of the equine cartilage
from the metacarpophalangeal III bone which measures
400 to 450 μm, considerably thinner than the human
cartilage used. The cartilage from the stifle joint of the
horse varies in thickness from 1,760 to 2,215 μm [51]
and may provide an alternative source of cartilage for
studies attempting to resolve changes in superficial and
deep layers of equine cartilage. Secondly, there was no
evidence for heterogeneity of peptide distribution that
had been previously identified in OA cartilage. This was
probably because the former study used severe OA car-
tilage while here only mild histological changes were
evident.Conclusions
The ex vivo imaging of aged and diseased cartilage pro-
vided ‘label-free’ and stain-free information about its
biomolecular composition. We identified a number of
potential degradation sites in some key ECM proteins as
well as markers of cartilage aging. With the resolving
power of MALDI-MSI certain to increase in the future
and improved methods to identify peptides in situ, fur-
ther MALDI-MSI studies using a greater age range may
help in understanding why aging cartilage is more prone
to OA.
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